Reizenstein P, Ogier C, Sjögren A M
Recent Results Cancer Res. 1980;75:29-36. doi: 10.1007/978-3-642-81491-4_5.
Lymphocytes were studied from 51 patients with acute myeloid leukemia (AML) in remission given chemotherapy (CT) maintenance alone or given chemoimmunotherapy (CIT) with BCG and viable allogeneic leukemic cells. CT lymphocytes reacted significantly more to PHA (P less than 0.05) if taken later than 100 days after remission than if taken earlier. CIT lymphocytes reacted less. Thus, the late CT lymphocytes reacted significantly more to nonspecific stimulators (PHA and allogeneic lymphocytes, P less than 0.01) than did late CIT lymphocytes or control lymphocytes. In consequence, the ratio of reactions to specific (leukemic myeloblasts) over nonspecific stimulators was significantly higher in CIT (P less than 0.01) than in CT lymphocytes. Results may indicate nonspecific immunostimulation during CT, and also some relative specific sensitization to allogeneic myeloblasts during CIT.
对51例急性髓系白血病(AML)缓解期患者的淋巴细胞进行了研究,这些患者单独接受化疗(CT)维持治疗,或接受卡介苗(BCG)和有活力的异基因白血病细胞的化学免疫疗法(CIT)。如果缓解后100天以后采集CT淋巴细胞,其对PHA的反应显著高于缓解后100天以内采集的淋巴细胞(P<0.05)。CIT淋巴细胞的反应较弱。因此,晚期CT淋巴细胞对非特异性刺激物(PHA和异基因淋巴细胞,P<0.01)的反应显著高于晚期CIT淋巴细胞或对照淋巴细胞。结果表明,CIT中对特异性刺激物(白血病成髓细胞)与非特异性刺激物反应的比值显著高于CT淋巴细胞(P<0.01)。结果可能表明CT期间存在非特异性免疫刺激,以及CIT期间对异基因成髓细胞存在一定的相对特异性致敏。